HLTW:PA:PA-Multi Units Luxembourg - Lyxor MSCI World Health Care TR UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 502

Change

0.00 (0.00)%

Market Cap

USD 0.75B

Volume

603.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The Sub-Fund is an index-tracking UCITS passively managed. The Reference Currency of the Sub-Fund is the Euro (EUR). The investment objective of sub-fund is to track both the upward and the downward evolution of the MSCI World Health Care Index " Net Total Return (the Index) denominated in US Dollars - while minimising the volatility of the difference between the return of the Sub-Fund and the return of the Index (the "Tracking Error"). The anticipated level of the tracking error under normal market conditions is expected to be up to 0.50%.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-23 )

ETFs Containing HLTW:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.09% 66% D+ 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.09% 65% D 62% D
Trailing 12 Months  
Capital Gain 4.25% 25% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.25% 21% F 46% F
Trailing 5 Years  
Capital Gain 51.48% 58% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.48% 55% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 10.35% 58% F 64% D
Dividend Return 10.35% 79% B- 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.80% 84% B 90% A-
Risk Adjusted Return 117.51% 96% N/A 97% N/A
Market Capitalization 0.75B 74% C 75% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike